Khondrion is a clinical-stage biopharmaceutical company developing innovative therapies for mitochondrial diseases. By leveraging a deep understanding of mitochondrial biology, the company is at the forefront of advancing treatments for these debilitating conditions. The company's lead drug candidate, sonlicromanol, is currently in clinical development for primary mitochondrial diseases.

Khondrion's commitment to scientific excellence and patient well-being drives its ongoing research and development efforts. The company is actively exploring the potential of sonlicromanol and other compounds in its pipeline to address a wide range of mitochondrial disorders. By collaborating with patient organizations and a global network of experts, Khondrion is accelerating the development of life-changing therapies for individuals affected by mitochondrial diseases.